[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2023003327A1 - Inhibidores de la interaccion de menina-mll - Google Patents

Inhibidores de la interaccion de menina-mll

Info

Publication number
CL2023003327A1
CL2023003327A1 CL2023003327A CL2023003327A CL2023003327A1 CL 2023003327 A1 CL2023003327 A1 CL 2023003327A1 CL 2023003327 A CL2023003327 A CL 2023003327A CL 2023003327 A CL2023003327 A CL 2023003327A CL 2023003327 A1 CL2023003327 A1 CL 2023003327A1
Authority
CL
Chile
Prior art keywords
menin
inhibitors
mll
mll interaction
interaction
Prior art date
Application number
CL2023003327A
Other languages
English (en)
Inventor
Cacatian Salvación
S Kulkarni Santosh
Kumar Samanta Swapan
Venkat Reddy Virsinha
M Mcgeehan Gerard
H Miller William
Paul Camp Nicholas
Original Assignee
Syndax Pharmaceuticals Inc
Vitae Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc, Vitae Pharmaceuticals Llc filed Critical Syndax Pharmaceuticals Inc
Publication of CL2023003327A1 publication Critical patent/CL2023003327A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a inhibidores de la Fórmula (0), o u estereoisómero de ellos o una sal farmacéuticamente aceptable de ellos, de la interacción de la menina con la MLL y las proteínas de fusión de la MLL, composiciones farmacéuticas que las contienen y su uso en el tratamiento del cáncer y de otras enfermedades
CL2023003327A 2021-05-14 2023-11-08 Inhibidores de la interaccion de menina-mll CL2023003327A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163188704P 2021-05-14 2021-05-14

Publications (1)

Publication Number Publication Date
CL2023003327A1 true CL2023003327A1 (es) 2024-05-03

Family

ID=84029448

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003327A CL2023003327A1 (es) 2021-05-14 2023-11-08 Inhibidores de la interaccion de menina-mll

Country Status (14)

Country Link
US (1) US11919901B2 (es)
EP (1) EP4337203A1 (es)
JP (1) JP2024517945A (es)
KR (1) KR20240047338A (es)
CN (1) CN117956992A (es)
AR (1) AR125866A1 (es)
AU (1) AU2022274325A1 (es)
BR (1) BR112023023463A2 (es)
CA (1) CA3213074A1 (es)
CL (1) CL2023003327A1 (es)
IL (1) IL308476A (es)
MX (1) MX2023013515A (es)
TW (1) TW202311262A (es)
WO (1) WO2022241265A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11919901B2 (en) 2021-05-14 2024-03-05 Syndax Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
WO2024046457A1 (en) * 2022-09-02 2024-03-07 Hutchmed Limited Triazine compounds and uses thereof
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124477A (en) 1996-06-27 2000-09-26 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5820915A (en) 1996-06-27 1998-10-13 Bioavailability Systems, L.L.C. Method for the preparation of a first-pass effective citrus-derived substance and product thereof
US5990154A (en) 1997-05-30 1999-11-23 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds and citrus extract
US6248776B1 (en) 1997-08-26 2001-06-19 Bioavailability Systems, L.L.C. Anti-first-pass effect compounds
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
US6063809A (en) 1997-08-26 2000-05-16 Bioavailability Systems, Llc Anti-first-pass effect compounds
US5993887A (en) 1998-06-29 1999-11-30 Bioavailability Systems, L.L.C. Safe citrus juice and process for preparation
WO2004037827A1 (en) 2000-10-20 2004-05-06 Bioavailability Systems, Llc Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates
EP1732891A4 (en) 2004-03-11 2009-05-06 Sequoia Pharmaceuticals Inc RESISTANT PREVENTIVE INHIBITORS FOR RETROVIRAL PROTEASES
EP2422780A1 (en) 2004-05-07 2012-02-29 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
US20090281114A1 (en) 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
SG194219A1 (en) 2011-06-10 2013-11-29 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US9216993B2 (en) 2013-03-13 2015-12-22 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2015108940A2 (en) 2014-01-14 2015-07-23 The Trustees Of The University Of Pennsylvania Tailored combinatorial epigenetic therapies for p53 gain-of-function tumors
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
CA2956962A1 (en) 2014-08-13 2016-02-18 Epizyme, Inc. Combination therapy for treating cancer
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
RU2018126774A (ru) 2015-12-22 2020-01-23 Витэ Фармасьютикалз, Инк. Ингибиторы менин-mll взаимодействия
EP3407884A4 (en) 2016-01-26 2019-09-11 Memorial Sloan-Kettering Cancer Center TARGETING OF CHROMATIN REGULATORS FOR THE INHIBITION OF LEUKEMOGENIC GENE EXPRESSION INNPM1
JP7000333B2 (ja) 2016-03-16 2022-02-10 クラ オンコロジー，インク． メニン－ｍｌｌの架橋された二環式阻害剤及びその使用方法
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
MX2018015252A (es) 2016-06-10 2019-04-25 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-leucemia de linaje mixto.
IL265028B (en) 2016-09-16 2022-09-01 Vitae Pharmaceuticals Llc Inhibitors of the menin-mil interaction
EP3728260A4 (en) 2017-12-20 2021-08-11 Janssen Pharmaceutica NV SPIRO EXO-AZA INHIBITORS OF MENIN-MLL INTERACTION
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
BR112020020059A2 (pt) 2018-03-30 2021-03-30 The Regents Of The University Of Michigan Compostos de piperidina como inibidores de menin covalentes
CA3111066A1 (en) 2018-09-13 2020-03-19 Merck Sharp & Dohme Corp. Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
JP7536767B2 (ja) 2018-12-31 2024-08-20 バイオメア フュージョン，インコーポレイテッド メニン－ｍｌｌ相互作用の不可逆的阻害剤
EP4132932A4 (en) 2020-04-07 2024-04-17 Syndax Pharmaceuticals, Inc. COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF
US11919901B2 (en) 2021-05-14 2024-03-05 Syndax Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
TW202320796A (zh) 2021-08-11 2023-06-01 美商拜歐米富士恩股份有限公司 用於糖尿病的menin-mll相互作用之共價抑制劑

Also Published As

Publication number Publication date
IL308476A (en) 2024-01-01
AU2022274325A1 (en) 2023-10-05
WO2022241265A1 (en) 2022-11-17
US20230021684A1 (en) 2023-01-26
TW202311262A (zh) 2023-03-16
KR20240047338A (ko) 2024-04-12
CN117956992A (zh) 2024-04-30
US11919901B2 (en) 2024-03-05
EP4337203A1 (en) 2024-03-20
CA3213074A1 (en) 2022-11-17
AR125866A1 (es) 2023-08-23
BR112023023463A2 (pt) 2024-01-30
MX2023013515A (es) 2024-02-29
JP2024517945A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
CL2023003327A1 (es) Inhibidores de la interaccion de menina-mll
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
CO2017008862A2 (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n’-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quinoxalin-6-il]etano-1,2-diamina
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
PE20161170A1 (es) Composiciones farmaceuticas que comprenden azd9291
ECSP22018571A (es) Degradadores bifuncionales de brd9 y sus métodos de uso
UY29825A1 (es) Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
AR127501A1 (es) Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos
CO2022002731A2 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
CL2024002023A1 (es) Inhibidor del inflamosoma nlrp3 y uso del mismo
CL2023000387A1 (es) Derivados de dioxoloisoquinolinona novedosos y uso de los mismos
CO2022015428A2 (es) Compuesto de oxofenilarsina deuterada y uso del mismo
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
AR051797A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
AR115883A1 (es) Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
CL2023002285A1 (es) Fracciones que prolongan la semivida y métodos de uso de estas
AR115921A1 (es) Ácido isolitocólico o ácido isoalolitocólico y derivados deuterados de los mismos para prevenir y tratar enfermedades asociadas a clostridium difficile
AR103719A1 (es) Composición líquida tópica para el lavado intrauterino que contiene melatonina
DOP2021000028A (es) Formulaciones de dendrímeros
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
BR112021011368A2 (pt) Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos